A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer???s Disease
- 1 January 2003
- journal article
- clinical trial
- Published by Springer Nature in Drugs & Aging
- Vol. 20 (10) , 777-789
- https://doi.org/10.2165/00002512-200320100-00006
Abstract
Objective To compare the long-term efficacy and safety of galantamine 24 mg/day and donepezil 10 mg/day in patients with Alzheimer’s disease.Keywords
This publication has 41 references indexed in Scilit:
- Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase InhibitorsClinical Pharmacokinetics, 2002
- Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trialJournal of Neurology, Neurosurgery & Psychiatry, 2001
- Modulation of Nicotinic Receptor Activity in the Central Nervous SystemAlzheimer Disease & Associated Disorders, 2001
- The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled TrialDementia and Geriatric Cognitive Disorders, 1996
- Assessment of Activities of Daily Living in Dementia: Development of the Bristol Activities of Daily Living ScaleAge and Ageing, 1996
- The Neuropsychiatric InventoryNeurology, 1994
- The Screen for Caregiver BurdenThe Gerontologist, 1991
- Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivoLife Sciences, 1990
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- “Mini-mental state”Journal of Psychiatric Research, 1975